TrialInflammopharmacology2024

Trivalent chromium versus baricitinib for rheumatoid arthritis treatment: first phase 2/3 randomized controlled trial, is trivalent chromium the upcoming immune-modulator?

Sally S Hassouna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.